Study of KN026 Monotherapy or Combined With Chemotherapy in Patients With Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer Interventions:   Drug: KN026 combination;   Drug: KN026 monotherapy Sponsor:   Jiangsu Alphamab Biopharmaceuticals Co., Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials